A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
Status:
Completed
Trial end date:
2020-07-23
Target enrollment:
Participant gender:
Summary
This is a multicenter， open-label study to evluate the efficacy and safety of a novel PARP
1/2 inhibitor fluzoparib （SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer.